The SMILE Study — Safety of Methotrexate in Combination with Leflunomide in Rheumatoid Arthritis

REFERENCES

1. 1.↵
   1. Lee SS,
   2. Park YW,
   3. Park JJ,
   4. Kang YM,
   5. Nam EJ,
   6. Kim SI,
   7. et al.

   Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis. Scand J Rheumatol 2009;38:11–4.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Kremer JM,
   2. Genovese MC,
   3. Cannon GW,
   4. Caldwell JR,
   5. Cush JJ,
   6. Furst DE,
   7. et al.

   Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:726–33.

   OpenUrlPubMed
3. 3.↵
   1. Mladenovic V,
   2. Domljan Z,
   3. Rozman B,
   4. Jajic I,
   5. Mihajlovic D,
   6. Dordevic J,
   7. et al.

   Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995;38:1595–603.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Smolen JS,
   2. Kalden JR,
   3. Scott DL,
   4. Rozman B,
   5. Kvien TK,
   6. Larsen A,
   7. et al.

   Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999;353:259–66.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Strand V,
   2. Cohen S,
   3. Schiff M,
   4. Weaver A,
   5. Fleischmann R,
   6. Cannon G,
   7. et al.

   Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999;159:2542–50.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Weinblatt ME,
   2. Kremer JM,
   3. Coblyn JS,
   4. Maier AL,
   5. Helfgott SM,
   6. Morrell M,
   7. et al.

   Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999;42:1322–8.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. National Institutes of Health-National Cancer Institute

   . Common terminology criteria for adverse events (CTCAE). Version 4.03,14 June 2010. Washington, DC: U.S. Department of Health and Human Services; 2010. [Internet. Accessed Nov 8, 2012.] Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
8. 8.↵
   1. Smolen JS,
   2. Landewe R,
   3. Breedveld FC,
   4. Dougados M,
   5. Emery P,
   6. Gaujoux-Viala C,
   7. et al.

   EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964–75.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Alcorn N,
   2. Saunders S,
   3. Madhok R

   . Benefit-risk assessment of leflunomide: An appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 2009;32:1123–34.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Curtis JR,
    2. Beukelman T,
    3. Onofrei A,
    4. Cassell S,
    5. Greenberg JD,
    6. Kavanaugh A,
    7. et al.

    Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis 2010;69:43–7.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Behrens F,
    2. Koehm M,
    3. Burkhardt H

    . Update 2011: Leflunomide in rheumatoid arthritis — strengths and weaknesses. Curr Opin Rheumatol 2011;23:282–7.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Singer O,
    2. Gibofsky A

    . Methotrexate versus leflunomide in rheumatoid arthritis: What is new in 2011? Curr Opin Rheumatol 2011;23:288–92.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Mayall B,
    2. Poggi G,
    3. Parkin JD

    . Neutropenia due to low-dose methotrexate therapy for psoriasis and rheumatoid arthritis may be fatal. Med J Aust 1991;155:480–4.

    OpenUrlPubMed
14. 14.↵
    1. Bourré-Tessier J,
    2. Haraoui B

    . Methotrexate drug interactions in the treatment of rheumatoid arthritis: A systematic review. J Rheumatol 2010;37:1416–21.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Kaltwasser JP,
    2. Nash P,
    3. Gladman D,
    4. Rosen CF,
    5. Behrens F,
    6. Jones P,
    7. et al.

    Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50:1939–50.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Scott DL

    . Interstitial lung disease and disease modifying anti-rheumatic drugs. Lancet 2004;363:1239–40.

    OpenUrlPubMed
17. 17.↵
    1. Sawada T,
    2. Inokuma S,
    3. Sato T,
    4. Otsuka T,
    5. Saeki Y,
    6. Takeuchi T,
    7. et al.

    Leflunomide-induced interstitial lung disease: Prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology 2009;48:1069–72.

    OpenUrlAbstract/FREE Full Text